Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis

Medically reviewed by Carmen Pope, BPharm. Last updated on March 27, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, March 27, 2025 -- Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK inhibitor-naive patients, according to a study published online March 10 in Nature Medicine.

Raajit K. Rampal, M.D., Ph.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a phase 3 study (MANIFEST-2) involving JAK inhibitor-naive patients with myelofibrosis who were randomly assigned to receive pelabresib 125 mg once daily for 14 days followed by a seven-day break or to placebo combined with ruxolitinib 10 or 15 mg twice daily (214 and 216 patients, respectively).

The researchers found that the primary end point of reduction in spleen volume of ≥35 percent from baseline at week 24 was met in 65.9 and 35.2 percent of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. The absolute change in total symptom score (TSS) was –15.99 and –14.05, respectively; a ≥50 percent decrease from baseline in TSS response at week 24 was achieved in 52.3 and 46.3 percent, respectively, for pelabresib-ruxolitinib and placebo-ruxolitinib. The most common treatment-emergent adverse events were thrombocytopenia (occurring in 52.8 and 37.4 percent, respectively) and anemia (44.8 and 55.1 percent, respectively).

"The phase 3 MANIFEST-2 study provides important insights into disease biology and modification, supporting the combination of pelabresib plus ruxolitinib for JAK inhibitor-naive patients with myelofibrosis," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Novartis; the MANIFEST-2 study was funded by Constellation Pharmaceuticals, a Novartis Company.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords